Oestrogen receptor expression in the normal and pre-cancerous breast

Journal of Pathology

Volumn 188, Issue 3, 1999, Pages 237-244

  Shoker, Balvinder S ^a   Jarvis, Christine ^a   Sibson, D Ross ^b   Walker, Carol ^b   Sloane, John P ^a,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE HOSPITAL   (United Kingdom)

^c Department of Pathology Duncan Building ^*  (United Kingdom)

Author keywords

Atypical ductal hyperplasia; Breast; Ductal carcinoma in situ; Hyperplasia of usual type; Oestrogen receptor

Indexed keywords

ESTROGEN RECEPTOR;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER RISK; CELLULAR DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

EID: 0032980947     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8     Document Type: Article

References (29)

1. Kelsey JL, Gammon MD, John EM. Reproductive and hormonal risk factors: reproductive factors and breast cancer. Epidemiologic Reviews 1993; 15(1): 36-47.
2. King RJB. Oestrogen-receptors: an overview of recent advances in their structure and function. Proc R Soc Edin 1989; 95B: 133-144.
3. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997; 76(3): 401-405.
4. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990-994.
5. Goodman MJ, Bulbrook RD, More JW. The distribution of estradiol in the sera of normal Caucasian, Chinese, Filipina, Hawaiian and Japanese women living in Hawaii. Eur J Cancer Clin Oncol 1988; 24: 1855-1860.
6. Petersen OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987; 47: 5748-5751.
7. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-4991.
8. Williams G, Anderson E, Howell A, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991; 48: 206-210.
9. Walker RA, Cowl J, Dhadly PP, Jones JL. Oestrogen receptor, epidermal growth factor receptor and oncoprotein expression in non-involved tissue of cancerous breasts. The Breast 1992; 2: 87-91.
10. Walker KJ, McClelland RA, Candlish W, Blarney RW, Nicholson RI. Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer 1992; 28(1): 34-37.
11. Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 1992; 65: 601-607.
12. Ricketts D, Turnbull L, Ryall G, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991; 51: 1817-1822.
13. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
14. London SJ, Connolly JL, Schmitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267: 941-944.
15. Bodian CA, Perzin KH, Lattes R, Hoffman P, Abernathy TG. Prognostic significance of benign proliferative breast disease. Cancer 1993; 71: 3896-3907.
16. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988; 128: 467-477.
17. National Co-ordinating Group for Breast Screening Pathology. Pathology Reporting in Breast Cancer Screening. 2nd ed. NHSBSP Publication No. 3. 1997.
18. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992; 23: 1095-1097.
19. Giri DD, Dundas SAC, Nottingham JF, Underwood JCE. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575-584.
20. Eckert RL, Katzenellenbogen BS. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 1982; 42: 139-144.
21. Boyd M, Hildebrandt RH, Bartow SA. Expression of the estrogen receptor gene in developing and adult human breast. Breast Cancer Res Treat 1996; 37(3): 243-251.
22. Boecker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part 1: normal breast and benign proliferative lesions. Virchovs Archiv A Pathol Anat 1992; 421: 315-322.
23. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP. Detection of loss of heterozygosity indicates that mammary hyperplasia of usual type is a clonal, neoplastic proliferation. Lab Invest 1996; 74: 129-135.
24. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D messenger RNA distinguishes invasive and in situ breast carcinomas from non malignant lesions. Nature Medicine 1995; 1: 1257-1260.
25. Musgrove ET, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577-2587.
26. Gillett CE, Lee AHS, Millis RR, Barnes DM. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 1998; 184: 396-400.
27. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators Cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions. Am J Path 1997; 150: 15-23.
28. Sloane JP, Ellman R, Anderson TJ, et al. Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U.K. National Coordinating Group for Breast Screening Pathology. Eur J Cancer 1994; 30A: 1414-1419.
29. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. Virchows Archiv 1999; 434: 3-10.